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Abstract
Children and young adults with heart disease appear to be at increased risk of developing cancer, although the reasons for
this are unclear. A cohort of 11,270 individuals, who underwent cardiac catheterizations while aged B 22 years in the UK,
was established from hospital records. Radiation doses from cardiac catheterizations and CT scans were estimated. The
cohort was matched with the NHS Central Register and NHS Transplant Registry to determine cancer incidence and
transplantation status. Standardized incidence ratios (SIR) with associated confidence intervals (CI) were calculated. The
excess relative risk (ERR) of lymphohaematopoietic neoplasia was also calculated using Poisson regression. The SIR was
raised for all malignancies (2.32, 95% CI 1.65, 3.17), lymphoma (8.34, 95% CI 5.22, 12.61) and leukaemia (2.11, 95% CI
0.82, 4.42). After censoring transplant recipients, post-transplant, the SIR was reduced to 0.90 (95% CI 0.49, 1.49) for all
malignancies. All lymphomas developed post-transplant. The SIR for all malignancies developing 5 years from the first
cardiac catheterization (2 years for leukaemia/lymphoma) remained raised (3.01, 95% CI 2.09, 4.19) but was again reduced
after censoring transplant recipients (0.98, 95% CI 0.48, 1.77). The ERR per mGy bone marrow dose for lympho-
haematopoietic neoplasia was reduced from 0.541 (95% CI 0.104, 1.807) to 0.018 (95% CI - 0.002, 0.096) where
transplantation status was accounted for as a time-dependent background risk factor. In conclusion, transplantation appears
to be a large contributor to elevated cancer rates in this patient group. This is likely to be mainly due to associated
immunosuppression, however, radiation exposure may also be a contributing factor.
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Introduction
Information on cancer rates among children and young
adults (\ 22 years) with congenital or acquired heart
conditions is limited. A small number of studies have been
published [1–7], suggesting relatively high cancer inci-
dence and mortality, compared to the general population.
Potential explanations include shared genetic or environ-
mental factors, immunosuppression, lifestyle, and radiation
exposure [3, 5]. Children with heart disease are subjected
to a number of forms of medical x-ray examinations,
including computed tomography (CT), cardiac catheteri-
zations and general radiography [8–11]. Although radio-
graphs comprise the majority of procedures, the majority of
the cumulative radiation dose in this patient group (around
80%) comes from CT and catheterizations [8, 12]. Diag-
nostic medical radiation exposure has increased substan-
tially in recent decades among this patient group [9]. The
long-term impact of this exposure is difficult to determine,
however. In this study, we established a cohort of 11,270
patients who had undergone cardiac catheterizations before
22 years of age. We then conducted two analyses; (1) an
overall assessment of the incidence of all malignant
tumours in the cohort, and (2) an assessment of the
potential contribution of radiation exposure and organ
transplantation on cancer rates.
Materials and methods
The study received a favourable ethical opinion from the
National Research Ethics Service Committee North East—
Newcastle and North Tyneside 2 Ethics Committee, along
with approval from the Confidentiality Advisory Group to
use patient identifiable data.
A retrospective cohort was created from hospital records
of examinations carried out in catheterization laboratories
at five participating English hospitals. Patients were eligi-
ble for inclusion if they had undergone at least one cardiac
catheterization procedure while aged under 22 years. An
initial cohort of 13,226 individuals was established.
Patients lacking full name or date of birth (n = 41), those
who were over 22 years old at the time of the first recorded
procedure (n = 133) along with patients who had under-
gone only trans-oesophageal echocardiography (n = 67),
non-cardiac fluoroscopy procedures (n = 122), Hickman
or other line insertions without any other cardiac
catheterization procedures (n = 31) were excluded, as
were those for whom radiation doses could not be esti-
mated (n = 78). Patients who had undergone isolated
pericardial effusion drainage (n = 70) were also excluded.
This left a cohort of 12,684 individuals which was matched
with the National Health Service Central Register
(NHSCR) to determine who had been diagnosed with a
neoplasm (reported as ICD-0 codes), the date of diagnosis,
and date and cause of death, where applicable. Fifty seven
patients were diagnosed with a neoplasm before the date of
their first recorded cardiac catheterization. These patients
were excluded from the analysis to reduce the impact of
reverse causality (i.e. malignancy or associated treatment
causing heart disease). 1357 cohort members could not be
matched by NHSCR. This left 11,270 patients who were
included in the analysis (Fig. 1). Details of this final cohort
are shown in Table 1.
Standardized incidence ratios (SIR) of malignancies,
with associated confidence intervals (CI), were calculated
as the ratio of observed to expected cases. Expected inci-
dence, from the date of the first cardiac catheterization, up
to the 1st of February 2014 was estimated from data pub-
lished by Cancer Research UK [13], representing sex- and
age-specific UK-wide rates. Observed/expected central
nervous system tumours included benign or borderline
malignant tumours (ICD codes D32-D33, D35.2-D35.4,
D42-D43, and D44.3-D44.5). However, these non-malig-
nant/borderline diseases, along with non-melanoma skin
cancer (NMSC), were not included in the observed/ex-
pected figures for the analysis of all malignancies
combined.
As organ transplantation, with associated immunosup-
pressant drug use, is also a known risk factor in cancer
development [14], we matched our cohort with the NHS
Transplant Registry, to determine which individuals had
received a transplanted organ, the organ involved, and the
date of transplant. We also examined notes fields in
Fig. 1 Flow diagram for cohort
394 R. W. Harbron et al.
123
procedure logbooks (available for 55% of cohort members)
and NHSCR death records for further information on
transplantation.
To assess the possible role of radiation exposure on
cancer incidence, expected cases were also calculated from
5 years following the first recorded cardiac catheterization
(2 years for leukaemia and lymphoma) to 1st February
2014. These represent the apparent minimum latency
periods for radiation induced tumours, based on previous
epidemiological studies [15].
For cardiac catheterizations, active bone marrow (ABM)
doses were estimated for 79% of examinations from dose
indicators recorded at the time of each procedure (kerma
area product in 71% and screening time for 8%), using a
dosimetry system based on Monte Carlo computer simu-
lations (PCXMC V2.0, STUK, Helsinki, Finland). This
incorporated information on typical values of x-ray energy,
beam projection angle and field size extracted from a
review of clinical images and structured dose reports. For
the remaining 21% of examinations for which no dose
indicator was recorded, estimated doses were calculated
based on the median doses for each procedure type at the
same hospital, using the same equipment, in which dose
indicators were recorded. Information on CT scans was
obtained from a cohort of children and young adults
scanned in Great Britain between 1983 and 2013 [16]. CT
Table 1 Details of cohort
Characteristic Whole cohort Transplant recipients Casesa
Sex
Male (% of whole cohort) 5612 (50%) 247 (49%) 36 (49%)
Female 5118 (45%) 242 (48%) 34 (47%)
Unknown 540 (5%) 20 (4%) 3 (4%)
Total 11,270 509 73
Patient age/year of birth
Median age at 01/02/2014 [10th, 90th percentiles] 13.5 y [3.0, 25.1] 18.9 y [8.0, 28.7] 24.0 y [8.5, 33.7]
Born\ 1980 [% of total] 217 [2%] 27 [5%] 9 [12%]
Born 1980–1989 1346 [12%] 135 [27%] 35 [48%]
Born 1990–1999 4156 [37%] 209 [42%] 17 [23%]
Born 2000–2009 4486 [40%] 118 [24%] 12 [16%]
Born[ 2010 1065 [9%] 11 [2%] 0
Cardiac catheterizations
Median age at first recorded procedure [10th, 90th percentiles] 3.2 y [0.1, 15.5] 9.0 y [1.1, 16.8] 11.6 y [0.9, 17.9]
Mean number of procedures [median, 10th, 90th percentiles] 1.5 [1, 1, 3] 4.5 [1, 4, 10] 3.4 [1, 2, 8]
1 procedure [% of total] 8489 [75%] 124 [25%] 36 [49%]
2 procedures 1555 [14%] 67 [13%] 9 [12%]
3 procedures 580 [5%] 57 [11%] 7 [10%]
4 procedures 229 [2%] 44 [9%] 2 [3%]
5 procedures 150 [1%] 53 [11%] 5 [7%]
[ 5 procedures 267 [2%] 155 [31%] 14 [19%]
Computed tomography
Median age at first recorded scan [10th, 90th percentiles] 5.1 y [0.1, 17.8] 8.7 y [1.2, 17.7] 9.9 y [2.4, 20.6]
Mean number of procedures [median, 10th, 90th percentiles] 0.4 [0, 0, 1] 2.7 [1, 0, 8.2] 4.9 [1, 0, 14]
No scans [% of total] 9666 [86%] 238 [47%] 35 [48%]
1 scan 760 [7%] 74 [15%] 7 [10%]
2 scans 352 [3%] 47 [9%] 2 [3%]
3 scans 187 [2%] 32 [6%] 3 [4%]
4 scans 84 [1%] 24 [5%] 2 [3%]
5 scans 60 [1%] 19 [4%] 4 [5%]
[ 5 scans 161 [1%] 75 [15%] 20 [27%]
SD standard deviation, y years
aMalignant, borderline malignant and benign tumours
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doses were estimated based on the methodology of Kim
et al. [17], taking into account the body part scanned,
patient age and year of scan (technological developments
have led to a reduction in doses over time).
The excess relative risk (ERR) of lymphohaematopoi-
etic neoplasia (leukaemia and lymphoma, including bor-
derline malignancies) in relation to cumulative ABM dose
was calculated using Poisson regression models, fitted by
maximum likelihood estimation, using the maxLik function
in R (R Foundation for Statistical Computing, Vienna,
Austria). The expected number of cases in stratum i was
assumed as:
PYi exp a0 þ a110 ai\5 þ a215 ai\10 þ a3110 ai\15ð
þa4115 ai\20 þ a5120 ai\25 þ a61ai  25
þa7TiÞ  1þ b1  Di þ b2  Ti  Dið Þ;
where PYi, ai and Di are the number of person-years of
follow-up, the average attained age and the accumulated
dose (in mGy) in stratum i, respectively. The covariate Ti
represents transplantation status. This regression function
is the product of the person-years as the offset, the expo-
nential term which represents the baseline rate and the
relative risk associated with the absorbed dose. The
parameter a7 represents the risk factor for transplant status,
while b1 represents the ERR per mGy and b2 represents the
ERR transplantation variation effect. Person-years were
calculated using the DATAB module of Epicure (HiroSoft
International Corporation, Seattle, USA). Both exclusion
and cumulative ABM dose lag periods were of 2 years.
Results
Across the whole cohort, 40 patients developed a malignant
neoplasm following their first recorded cardiac catheteri-
zation, after 92,629 years of follow-up (mean = 8.4 -
years). One patient developed two distinct diseases on
different occasions, giving a total of 41 malignancies, of
which 30 (73%) were leukaemia (n = 7) or lymphoma
(n = 23) (Table 2). There were no malignancies of the
breasts, lungs, stomach or oesophagus. The SIR was raised,
compared to UK-wide background rates (Table 3), for all
malignancies combined (2.32, 95% CI 1.65, 3.17) and
lymphoma (8.34, 95% CI 5.22, 12.61). The SIR was also
raised for leukaemia, though with a wide confidence
interval (2.11, 95% CI 0.82, 4.42).
In addition to the 41 malignancies, there were a further
33 diseases classified as benign or borderline malignancies,
including nine lymphoproliferative disorders and nine
intraepithelial neoplasia of the cervix/exocervix. In total,
73 patients developed a neoplasm, malignant or otherwise.
The majority of the 25 tumours with clearly defined
locations were in the abdomen/pelvis (n = 18) or head/-
neck (n = 6). There were no definite thoracic tumours (the
location of one melanoma was listed as ‘trunk’).
Transplantation
Among the cohort, 509 individuals received a transplanted
organ before February 2014. The majority of these trans-
plantations involved the heart only (80%), or heart and
lungs (5%). The mean age at transplantation was 9.2 years.
Twenty six malignancies developed among this patient
group (63% of malignancies in the cohort) including 23
lymphomas (all cases of this disease). The mean age at
diagnosis was 16.9 years for post-transplant malignancies,
compared to 15.1 among non-transplant patients. The
potential impact of transplantation on SIR was investigated
by censoring observations for transplant recipients at the
date of transplantation. This resulted in a reduction in the
SIR to 0.90 for all malignancies combined (95% CI 0.49,
1.49) (Table 3). The SIR for leukaemia was essentially
unchanged, however (2.19, 95% CI 0.85, 4.59). Thirteen
patients developed benign or borderline malignancies,
post-transplant, including 9 with lymphoproliferative dis-
order (100% of cases in the cohort). Three patients
developed NMSC. None of the patients developing cervical
intraepithelial neoplasia were identified as transplant
recipients.
Radiation exposure
Cohort members underwent a total of 17,154 recorded
cardiac catheterizations and 4372 CT scans, up to February
2012 (i.e. 2 years before end of follow-up). The majority of
patients had a single recorded catheterization (Table 1).
Estimated organ doses are shown in Table 4. The mean
ABM dose was 8.4 mGy. There were 384 patients with
estimated cumulative bone marrow doses less than
0.1 mGy and 60 with doses over 100 mGy. The most
common catheterizations were patent ductus arteriosus
occlusion, coronary angiography, atrial septal defect
occlusion and electrophysiology studies. The majority of
CT scans in these patients were of the head, chest, or chest
in combination with other body parts. A positive correla-
tion was seen between the number of cardiac catheteriza-
tions and the number of CT scans (Spearman’s q = 0.252,
95% CI 0.233, 0.272). Transplant recipients underwent a
total of 2395 recorded catheterization procedures and 1416
CT scans. The majority of these procedures (82%) and the
majority of the associated dose (75%) (Table 4) occurred
post-transplant, consistent with monitoring for rejection
and coronary allograft vasculopathy.
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The ‘post-latency’ SIR for malignancies developing at
least 5 years following the first recorded cardiac catheter-
ization (2 years for leukaemia or lymphoma), remained
raised for all malignancies (3.01, 95% CI 2.09, 4.19) and
lymphoma (9.15, 95% CI 5.66, 13.97) (Table 5) though
with somewhat wider confidence intervals. After censoring
observations for transplant recipients, the post-latency SIR
for all malignancies was reduced to 0.98 (95% CI 0.48,
1.77). A sensitivity analysis was performed by calculating
post-latency SIR after excluding all patients with cumula-
tive ABM doses less than 0.1 mGy. This resulted in a slight
increase in SIR for all malignancies to 3.04 (95% CI 2.11,
42.4) for the whole cohort, and 0.99 (95% CI 0.48, 1.79)
after censoring transplant recipients.
Table 2 Details of neoplasia (malignant or otherwise) diagnosed among cohort members
Neoplasm type: Whole cohort Post-transplant
Total Malignant Borderline or benign Malignant Borderline or benign
lymphohaematopoietic 44 30 14 23 10
Hodgkin’s lymphoma 4 4 0 4 0
Non-Hodgkin’s lymphoma 19 19 0 19 0
Lymphoproliferative disorder 9 0 9 0 9
Acute lymphoblastic leukaemia 3 3 0 0 0
Acute myeloid leukaemia 3 3 0 0 0
Other leukaemia 1 1 0 0 0
Other haematological neoplasia 5 0 5a 0 1
Sarcoma 3 2 1b 0 0
Central nervous system 4 2 2 1 0
Carcinoma/carcinoma in situ 16 4 12 2 3
Cervix/exocervix 10 1 9 0 0
Testes 2 2 0 0 0
Melanoma 1 1 0 0 0
Other 4 0 4 0 0
Total 74c 41 33 26 13
aIncludes polycythaemia vera
bUncertain diagnosis (dermatofibroma/fibrosarcoma)
cOne patient developed two diseases
Table 3 Standardized incidence
ratio (SIR) for malignancies
developing between the date of
each patient’s first recorded
cardiac catheterization and 1st
February 2014
Disease Observed Expected SIR [IQR]
All patients
All malignancies 41 17.66 2.32 [1.65, 3.17]
Leukaemia 7 3.31 2.11 [0.82, 4.42]
Lymphoma 23 2.76 8.34 [5.22, 12.61]
Hodgkin lymphoma 4 1.67 2.40 [0.60, 6.27]
Non-Hodgkin lymphoma 19 1.09 17.45 [10.36, 27.50]
Central nervous system 4 3.71 1.08 [0.27, 2.82]
After censoring post-transplant patients
All malignancies 15 16.72 0.90 [0.49, 1.49]
Leukaemia 7 3.19 2.19 [0.85, 4.59]
Lymphoma 0 2.59 –
Hodgkin lymphoma 0 1.56 –
Non-Hodgkin lymphoma 0 1.03 –
Central nervous system 3 3.54 0.85 [0.15, 2.54]
IQR interquartile range
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The ERR was calculated based on 36 malignant and
borderline malignant lymphohaematopoietic neoplasia (29
among transplant recipients) and a total of 74,405 person-
years (3446 for transplant recipients). Ignoring the trans-
plant status interaction term, i.e. b2 = 0, the ERR was
cb1 ¼ 0:018 mGy-1 (95% profile likelihood (PL) CI
- 0.002, 0.096). The hat symbol over the beta parameter
denotes the maximum likelihood estimator. Including the
transplant status interaction term cb1 ¼ 0:042 mGy-1 and
cb2 ¼  0:021. When transplant status information was not
taken into account at all, i.e. where a7 ¼ 0 and b2 = 0, the
ERR was cb1 ¼ 0:542 (95% PL lower bound: 0.104, Wald
based upper bound: 1.807). Where this latter model was
modified by censoring transplant patients post-transplant,
Table 4 Estimated cumulative organ doses, up to 1st February 2012 (2 years prior to end of follow-up), from cardiac catheterizations for cohort
members
Breastsa Lungs Oesophagus Thyroid ABM ABM (CC ? CT)
Mean organ dose (mGy) [IQR]
Whole cohort 33.1 [63.8] 42.9 [78.8] 26.2 [47.2] 1.6 [3.3] 6.6 [12.8] 8.8 [16.5]
Transplant recipients 49.4 [74.8] 80.7 [109.1] 48.3 [64.9] 2.3 [3.5] 15.8 [22.3] 28.3 [32.4]
Pre-transplant 16.5 [56.7] 20.0 [62.4] 11.5 [35.7] 0.7 [2.2] 3.1 [9.3] 6.6 [14.8]
Post-transplant 32.9 [53.6] 60.7 [94.4] 36.8 [56.8] 1.6 [2.8] 12.6 [20.6] 21.7 [29.2]
Casesb,c 63.7 [81.9] 80.6 [86.0] 43.3 [42.1] 2.0 [1.7] 14.2 [16.3] 20.9 [22.2]
Transplant recipient casesb,c 63.7 [81.9] 81.7 [78.7] 43.7 [38.9] 1.9 [1.7] 14.1 [13.3] 22.2 [20.8]
Median organ dose (mGy) [IQR]
Whole cohort 14.1 [5.1, 33.5] 20.2 [8.2, 46.2] 13.0 [5.4, 27.2] 0.7 [0.3, 1.6] 3.1 [1.2, 6.6] 3.1 [1.3, 9.3]
Transplant recipients 19.0 [5.7, 68.5] 39.5 [14.5, 100.2] 25.6 [9.6, 60.7] 1.2 [0.4, 2.7] 7.7 [2.7, 19] 16.9 [6.4, 37.2]
Pre-transplant 0.0 [0.0, 7.0] 0.0 [0.0, 10.4] 0.0 [0.0, 5.7] 0.0 [0.0, 0.4] 0.0 [0.0, 1.7] 0.0 [0.0, 6.4]
Post-transplant 9.3 [2.1, 37.5] 23.3 [5.7, 72.1] 15.9 [3.4, 44.4] 0.7 [0.2, 1.8] 4.7 [1.0, 14.5] 11.1 [2.5, 28.7]
Casesb,c 34.0 [7.3, 85.5] 59.5 [22.5, 99.1] 35.1 [15.9, 58.3] 1.5 [0.7, 3.1] 10.2 [3.0, 19.2] 12.7 [3.8, 30.6]
Transplant recipient casesb,c 34.0 [7.3, 85.5] 69.8 [24.6, 102.9] 36.9 [16.1, 58.4] 1.4 [0.8, 2.8] 11.9 [4.3, 19.5] 14.6 [7.2, 31.8]
ABM active bone marrow, ABM (CC ? CT) cumulative doses from both cardiac catheterizations and computed tomography combined, IQR
interquartile range
aFemale patients only
bCumulative dose up to 2 years prior to diagnosis
clymphohaematopoietic neoplasia, malignant and borderline, used in ERR models
Table 5 Standardized incidence
ratio (SIR) for malignancies
developing at least 5 years
following the first recorded
cardiac catheterization (2 years
for leukaemia and lymphoma)
Disease Observed Expected3 SIR [IQR]
All patients
All malignancies 36 11.98 3.01 [2.09, 4.19]
Leukaemia 4 2.31 1.73 [0.43, 4.53]
Lymphoma 22 2.40 9.15 [5.66, 13.97]
Hodgkin lymphoma 4 1.48 2.70 [0.68, 7.07]
Non-Hodgkin lymphoma 18 0.92 19.49 [11.39, 31.10]
Central nervous system 3 1.92 1.57 [0.28, 4.70]
After censoring post-transplant patients
All malignancies 11 11.26 0.98 [0.48, 1.77]
Leukaemia 4 2.22 1.80 [0.45, 4.71]
Lymphoma 0 2.25 –
Hodgkin lymphoma 0 1.38 –
Non-Hodgkin lymphoma 0 0.87 –
Central nervous system 2 1.82 1.10 [0.09, 4.11]
IQR interquartile range
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the ERR was 0.149 mGy-1 (95% PL CI 0.001, 0.564).
Omitting the absorbed dose information, i.e. b1 = 0 and
b2 ¼ 0, the risk effect of transplant status estimate was
ba7 ¼ 4:370, indicating that the risk of haematological
neoplasia was almost 80 times larger for patients who
underwent transplantation.
Discussion
This is the largest study to date investigating cancer inci-
dence among young people who have undergone cardiac
catheterizations, and the first to include detailed radiation
dose estimation and transplant registry linkage. The most
interesting finding was the large apparent impact of trans-
plantation on cancer rates in this patient group. Transplant
recipients are treated with immunosuppressive therapies,
including cyclosporine and tacrolimus [18], and receive
relatively high radiation doses, especially post-transplant.
Immunosuppression [14] and ionising radiation [19] are
both well-known risk factors for cancer development and
cannot be disentangled by SIR analysis alone. Our dose
response analysis modelled the impact of transplantation in
a similar manner to sex in similar radiation epidemiology
studies, albeit with transplantation status as a time-depen-
dent variable. The results of this analysis suggest radiation
exposure alone does not account for the high rates of
lymphohaematopoietic tumours among post-transplant
patients, which in turn suggests immunosuppression is the
dominant underlying cause. Furthermore, the apparent
impact of transplantation was greatest for lymphoma and
lymphoproliferative disorders; conditions strongly associ-
ated with immunosuppression [18, 20, 21], though rela-
tively weakly associated with radiation exposure (e.g.
[19]). In contrast, rates for leukaemia, a disease strongly
associated with radiation exposure [19, 22] but less so with
immunosuppression [20], were almost unaffected by cen-
soring transplant recipients.
The absence of any cancers of the lungs, breasts and
oesophagus was expected, despite the high mean dose to
these tissues (Table 4). These diseases are rare below age
35 years [23], even among individuals exposed to elevated
radiation levels [24]. Only 135 cohort members had
reached the age of 35 years by February 1st 2014. The lack
of cancers of the breasts, lungs or oesophagus should not be
regarded as evidence of no risk, at this stage of follow-up.
The drive to keep radiation exposures as low as reasonably
achievable must, therefore, be maintained.
We were only able to gather information on cardiac
catheterizations and CT. What may be termed ‘dark dose’;
exposure from other sources such as general radiography
and nuclear medicine, could be considerable for certain
individual patients, despite contributing only a small pro-
portion of the total cumulative dose for the whole cohort.
Uncertainties in dose estimates include measurement error
(i.e. kerma area product) and uncertainty in the conversion
factor from which organ doses are derived, due to variation
in beam angle, field size and x-ray energy. A further source
of uncertainty relates to the lack of dose indicator for 21%
of examinations, meaning organ doses needed to be esti-
mated based on era-specific median doses for which dose
indicators were available. For bone marrow, this figure was
3.1 mGy for examinations prior to 2003. Doses vary con-
siderably from one procedure to the next, however. For
example, the interquartile range for ABM dose was
1.65–5.60 mSv, while the 95th percentile was 18.3 mGy.
Future work will attempt to quantify these uncertainties
using 2D Monte Carlo techniques, allowing them to be
incorporated into risk estimates.
Other than transplantation, we had limited information
on other potential tumour-predisposing syndromes, such as
neurofibromatosis or ataxia telangiectasia. Around 55% of
examination records included a notes field in which rele-
vant history could be recorded, while other details could be
obtained from the cause of death for patients who died.
Four malignancies (all leukaemia) were found among
patients identified as having Down syndrome, versus 0.14
expected. Very few cases were identified among children
with the most serious congenital heart defects, including
hypoplastic left/right ventricles (1 case) transposition of the
great arteries or tetralogy of Fallot (no malignancies, one
NMSC). This analysis is limited, however, by the small
proportion of the cohort for whom examination notes were
available. Future studies would benefit from linkage with
congenital anomalies registries.
Comparison with previous studies
Three other studies have investigated cancer incidence or
mortality among children undergoing cardiac catheteriza-
tions. A retrospective cohort study of 4861 children who
underwent cardiac catheterisations between 1946 and 1968
in Ontario, Canada, reported 5 cancer deaths were
observed, compared to 4.8 expected, after 13 years of
follow-up [1]. A further study [2] using the same cohort
(reduced to 3915 members due to exclusion of patients
living outside the study area) reported a standardised
mortality ratio (SMR) of 1.2 (90% CI 0.6, 2.3), based on 7
cancer deaths versus 5.7 expected. The SIR was 0.75 (0.3,
1.2), based on 13 cancer cases observed versus 17.3
expected. As with the current study, a number of cancers
were reported in sites remote from the heart including the
tongue, testis (two cases), prostate, ovary, cervix, colon and
brain. Modan et al. [3] reviewed details of 674 Israeli
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children who underwent cardiac catheterizations between
1950 and 1970. Dose records were unavailable for 90% of
cohort members. The SIR was 2.3 (95% CI 1.2, 4.1), based
on 11 cases compared to 4.75 expected, including 4 lym-
phomas and 3 melanomas. At least six of the tumours
occurred in locations remote from the heart (testis, prostate,
bladder, inguinal lymph nodes and melanomas of the groin
and lower limb). The location of the others was unclear.
Interestingly, all cancers occurred in males, who repre-
sented 56% of the cohort.
Other studies have focused on cancer rates among
people with CHD, irrespective of whether or not they
underwent cardiac catheterizations. A recent study [5]
focussed on 31,961 Taiwanese patients of all ages, identi-
fied from insurance records, diagnosed with CHD between
1998 and 2006. The SIR for all cancer sites was 1.45 (95%
CI 1.25, 1.67). Around half of these patients had undergone
a catheterization procedure (48.9%) while 18.9% under-
went CT scanning. The most common cancers were
haematological (SIR = 4.04). Lymphomas were not anal-
ysed separately. Heart transplants are carried out in Taiwan
[25], though it is unclear how many patients had undergone
this procedure. Other studies have reported increased rates
of cancer among individuals with cardiovascular malfor-
mations, as part of wider studies investigating other forms
of congenital diseases [4, 6, 7]. Although the results of our
analysis are broadly consistent with previous studies, it
should be noted that the current cohort was established
from hospital records of patients undergoing cardiac
catheterizations, rather than from registers of congenital
malformations.
Our SIR figures can also be compared to more general
studies of children exposed to diagnostic x-rays (i.e. not
specifically cardiac patients). Hammer et al. [26] reported
SIRs of 0.99 for all cancers (95% CI 0.79, 1.22), 1.08 for
leukaemia (95% CI 0.74, 1.52) and 0.97 for lymphoma
(95% CI 0.52, 1.66) for 92,957 German children postna-
tally exposed to diagnostic x-rays. Average estimated doses
were very low (mean effective dose = 0.137 mSv, com-
pared to 13.1 mSv in the current study). The SIR for all
cancers was similar to that of the current study after cen-
soring transplant patients. Our SIR for leukaemia was
higher, though statistically compatible with that of Ham-
mer et al. [26]. Focussing only on CT scans, Krille et al.
[27, 28] reported raised SIRs for all cancers (1.82, 95% CI
1.29, 2.50), lymphoma (2.96, 95% CI 1.42, 5.45) and
leukaemia (1.72, 95% CI 0.89, 3.01). After excluding
patients at increased risk of cancer, SIR figures were
reduced to 1.54 for all cancers (95%: CI 1.05, 2.19), 1.79
for leukaemia (95% CI 0.92, 3.12) and 1.85 for lymphoma
(95% CI 0.68, 4.02). The impact of this change on lym-
phoma SIR was much smaller than found in the current
study, although Krille et al. [27, 28] did not have the
benefit of transplant registry linkage. Mean cumulative
bone marrow doses (11.7 mGy) were a little higher than in
the current study (8.8 mGy).
The average equivalent dose to bone marrow from
natural sources, including gamma rays and radon has been
estimated to be 1.5 mSv per year at age 1 year, falling to
1.3 mSv per year at age 15 years [29]. Thus, the mean
cumulative ABM dose from recorded medical exposures in
this group (8.3 mGy, equivalent to 8.3 mSv) is comparable
to around 5–6 years of background radiation. Background
gamma exposure has been associated with a relative risk
(RR) of 1.08 mGy-1 (95% CI 1.02, 1.16) for leukaemia
and non-Hodgkin lymphoma [22]; a figure higher than, but
statistically compatible with the ERR for lympho-
haematopoietic neoplasia in the current study.
Conclusion
Cancer rates among children and young adults who
undergo x-ray guided cardiac catheterizations are high,
compared to the general population. Despite transplant
recipients making up less than 5% of the cohort, these
individuals contributed more than 60% of observed
malignancies. While immunosuppression may be the most
likely explanation for this, the higher radiation doses
received by transplant recipients, post-transplant, may also
be a contributing factor. Further analysis is planned with an
enlarged cohort, congenital anomaly registry linkage,
extended follow-up and pooling with cohorts from other
countries (e.g. [30]). We recommend that future studies of
the cancer risks from cardiac x-ray procedures take steps to
identify transplant recipients, ideally through registry
linkage.
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